NCT02979639View on ClinicalTrials.gov

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

404

Participants

Timeline

Start Date

January 16, 2017

Primary Completion Date

April 12, 2017

Study Completion Date

May 24, 2018

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.

Trial Locations (11)

15401

GSK Investigational Site, Uniontown

23507

GSK Investigational Site, Norfolk

27705

GSK Investigational Site, Durham

29303

GSK Investigational Site, Spartanburg

64114

GSK Investigational Site, Kansas City

80045

GSK Investigational Site, Aurora

80906

GSK Investigational Site, Colorado Springs

80922

GSK Investigational Site, Colorado Springs

83646

GSK Investigational Site, Meridian

94612

GSK Investigational Site, Oakland

97330

GSK Investigational Site, Corvallis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02979639 - Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age | Biotech Hunter | Biotech Hunter